Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER+ and AR+ Breast Cancer”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Study completedNCT02463032
What this trial is testing

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

Who this might be right for
ER+ and AR+ Breast Cancer
GTx 136
Testing effectiveness (Phase 2)Ended earlyNCT02000375
What this trial is testing

A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)

Who this might be right for
Metastatic BreastcancerEstrogen Receptor Positive Breast CancerEstrogen Receptor Negative Neoplasm+3 more
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 20
Early research (Phase 1)UnknownNCT05673694
What this trial is testing

To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Changchun GeneScience Pharmaceutical Co., Ltd. 70
Early research (Phase 1)Ended earlyNCT00972023
What this trial is testing

DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Who this might be right for
Breast Cancer
Barbara Ann Karmanos Cancer Institute 1
Testing effectiveness (Phase 2)WithdrawnNCT01612910
What this trial is testing

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

Who this might be right for
Breast Cancer Female
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT00468715
What this trial is testing

Bicalutamide in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 28
Early research (Phase 1)Active Not RecruitingNCT04360941
What this trial is testing

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast Cancer+3 more
Royal Marsden NHS Foundation Trust 45
Testing effectiveness (Phase 2)Study completedNCT02971761
What this trial is testing

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Who this might be right for
Androgen Receptor PositiveEstrogen Receptor NegativeHER2/Neu Negative+3 more
City of Hope Medical Center 18
Testing effectiveness (Phase 2)UnknownNCT02910050
What this trial is testing

Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Xu fei 58
Testing effectiveness (Phase 2)WithdrawnNCT02746328
What this trial is testing

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Who this might be right for
ER+ and AR+ Breast Cancer
GTx
Testing effectiveness (Phase 2)Looking for participantsNCT06099769
What this trial is testing

Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 201
Testing effectiveness (Phase 2)Study completedNCT00755885
What this trial is testing

Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Research UK 77
Large-scale testing (Phase 3)Ended earlyNCT04869943
What this trial is testing

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Veru Inc. 52
Early research (Phase 1)Study completedNCT02672475
What this trial is testing

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+3 more
Vanderbilt-Ingram Cancer Center 29
Testing effectiveness (Phase 2)Looking for participantsNCT05573126
What this trial is testing

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer
Ellipses Pharma 95
Testing effectiveness (Phase 2)Study completedNCT01988324
What this trial is testing

AR and ER Imaging in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
University Medical Center Groningen 24
Testing effectiveness (Phase 2)Study completedNCT02130700
What this trial is testing

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

Who this might be right for
Prostate Cancer
Innocrin Pharmaceutical 17
Testing effectiveness (Phase 2)Ended earlyNCT02457910
What this trial is testing

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
Vanderbilt-Ingram Cancer Center 30